TABLE 1

Absorbed Doses for Tumors and Organs at Risk in ¹⁷⁷Lu PRRT Studies

		Absorbed dose (Gy/GBq)
Organ or lesion	No. of patients	Median	Range	Mean ± SD	Method	Reference
Red marrow	6			0.07 ± 0.01	Blood	9
	61			0.04 ± 0.02	Blood	10
	15	0.02	0.01–0.13	0.034 ± 0.030	Blood	11
	12	0.03	0.02–0.06	0.04 ± 0.02	Blood	13
	200	0.02	0.01–0.05		Blood	14
	7	≤0.07^* (≤0.08^†)			SPECT	16
	10	0.04	0.02–0.06		Blood	33
Kidneys	6			0.88 ± 0.19	Planar	9
	61			0.90 ± 0.30	Planar	10
	16			0.97 ± 0.24	Planar	12
	16			0.90 ± 0.21	SPECT	12
	12	0.68	0.33–1.65	0.80 ± 0.35	Planar	13
	200	0.61	0.27–1.35		SPECT	14
	88		0.36–0.78	0.57 ± 0.09	Planar	15
	7	1.15^* (0.68^†)	0.54–2.16^* (0.34–1.82^†)	1.24 ± 0.49^* (0.84 ± 0.49^†)	SPECT	16
	10	0.62	0.45–17.74		Planar	33
	33		0.33–2.4	0.8 ± 0.3	Planar	42
Tumors	6		3.9–37.9		Planar	9
	61			9.7 ± 11.1	Planar	10
	16	6.7	0.1–20		SPECT	12
	88		1.3–4.8	3.41 ± 0.68	Planar	15
	7		2–11^* (1–11^†)		SPECT	16
	10		0.6–56		Planar	33
	24	6.8	1.4–23		SPECT	42

↵* Pretherapeutic.
↵† Posttherapeutic.